Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 8, 2010 Ryan McBride	Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool January 5, 2010 Brian Orelli	Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool October 31, 2011 Brian Orelli	When You've Got It, You've Got It Biogen keeps its good-news streak going.
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool June 21, 2010 Luke Timmerman	Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool December 26, 2007 Brian Lawler	Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment.
The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
BusinessWeek March 21, 2005 Catherine Arnst	On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection.
The Motley Fool July 23, 2008 Brian Lawler	No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.
The Motley Fool December 12, 2008 Brian Orelli	An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool October 22, 2008 Brian Orelli	Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places.
The Motley Fool April 22, 2011 MedCity News	Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments.
The Motley Fool May 10, 2005 Charly Travers	The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?
The Motley Fool November 8, 2007 Brian Lawler	Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
The Motley Fool April 17, 2009 Brian Orelli	When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future?
The Motley Fool July 24, 2007 Brian Lawler	Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line.
The Motley Fool September 4, 2009 Brian Orelli	Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
The Motley Fool December 13, 2007 Brian Lawler	Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool December 17, 2008 Brian Orelli	A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off.
The Motley Fool February 9, 2006 Stephen D. Simpson	Serono: On the Block and on the Clock Will the Swiss-based biotech be able to strike a good deal for shareholders?
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool November 1, 2006 Brian Lawler	Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool February 7, 2008 Brian Lawler	Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool April 8, 2010 Brian Orelli	Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult.
The Motley Fool December 21, 2011 Brian Orelli	A Biotech Garage Sale Exelixis sells off a preclinical program.
The Motley Fool April 25, 2008 Brian Lawler	Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
The Motley Fool September 21, 2006 Brian Lawler	Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note.
Chemistry World February 8, 2013 Andrew Turley	Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis.